Primary tumor-derived systemic nANGPTL4 inhibits metastasis

J Exp Med. 2023 Jan 2;220(1):e20202595. doi: 10.1084/jem.20202595. Epub 2022 Oct 21.

Abstract

Primary tumors and distant site metastases form a bidirectionally communicating system. Yet, the molecular mechanisms of this crosstalk are poorly understood. Here, we identified the proteolytically cleaved fragments of angiopoietin-like 4 (ANGPTL4) as contextually active protumorigenic and antitumorigenic contributors in this communication ecosystem. Preclinical studies in multiple tumor models revealed that the C-terminal fragment (cANGPTL4) promoted tumor growth and metastasis. In contrast, the N-terminal fragment of ANGPTL4 (nANGPTL4) inhibited metastasis and enhanced overall survival in a postsurgical metastasis model by inhibiting WNT signaling and reducing vascularity at the metastatic site. Tracing ANGPTL4 and its fragments in tumor patients detected full-length ANGPTL4 primarily in tumor tissues, whereas nANGPTL4 predominated in systemic circulation and correlated inversely with disease progression. The study highlights the spatial context of the proteolytic cleavage-dependent pro- and antitumorigenic functions of ANGPTL4 and identifies and validates nANGPTL4 as a novel biomarker of tumor progression and antimetastatic therapeutic agent.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiopoietin-Like Protein 4* / pharmacology
  • Angiopoietin-Like Protein 4* / therapeutic use
  • Angiopoietins / pharmacology
  • Angiopoietins / therapeutic use
  • Biomarkers, Tumor
  • Humans
  • Neoplasms* / diagnosis
  • Neoplasms* / drug therapy
  • Neoplasms* / metabolism
  • Peptide Fragments / pharmacology
  • Peptide Fragments / therapeutic use

Substances

  • Angiopoietin-Like Protein 4
  • Angiopoietins
  • Biomarkers, Tumor
  • peptide fragment cANGPTL4
  • Peptide Fragments
  • peptide fragment nANGPTL4